TTUVI

Glial tumours are the most common primary brain tumours, with an incidence of around 5/100,000/year. They represent a heterogeneous group of tumours, classified according to their histological grade (grades 1 to 4) and their molecular profile. Glioblastoma (grade 4) is the most common and most aggressive glial tumour in adults, characterised by significant intra-tumour heterogeneity and a poor prognosis, with a median survival of 14 to 16 months despite current treatments including surgery, radiotherapy, chemotherapy and targeted therapies. They therefore represent a real therapeutic challenge. The development of neoangiogenesis and cell invasion along white matter fibre bundles are known to be the main factors in resistance to glioma treatment[6]. The TTUVI (Tumors Transcranial Ultrasound Vascular Imaging) research project aims to develop a non-invasive 3D transcranial ultrasound vascular imaging technique for diagnosing brain tumours in humans and for monitoring the effectiveness of proposed treatments.

There are no benefits for this project at this time